---
title: "Cogent Biosciences, Inc. (COGT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/COGT.US.md"
symbol: "COGT.US"
name: "Cogent Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T14:03:31.414Z"
locales:
  - [en](https://longbridge.com/en/quote/COGT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/COGT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/COGT.US.md)
---

# Cogent Biosciences, Inc. (COGT.US)

## Company Overview

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.cogentbio.com](https://www.cogentbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.32 | 484 | - | - | - |
| PB | 9.34 | 386 | 35.83 | 27.17 | 10.01 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 69% |
| Overweight | 2 | 15% |
| Hold | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 32.42 |
| Highest Target | 72.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/COGT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/COGT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/COGT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/COGT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**